Transcranial sonography and [123I]FP-CIT SPECT disclose complementary aspects of Parkinson's disease.

Hyperechogenic signal of substantia nigra (SN) in transcranial sonography (TCS) and reduced striatal uptake in FP-CIT SPECT are common findings in idiopathic Parkinson's disease (PD). But so far it is unknown whether the extent of SN hyperechogenicity represents a correlate for the degeneration of presynaptic dopaminergic neurons in PD. We performed TCS and 123I-labelled N-(3-fluoropropyl)-2ss-carbomethoxy-3ss-(4-iodophenyl)nortropane ([123I]FP-CIT) SPECT in 53 patients with PD. Striatal FP-CIT uptake was quantified by measuring the striatal/posterior lobe binding of [123I]FP-CIT. SN echogenicity was quantified by planimetric measurement of the maximum extension of hyperechogenic signals. We found no correlation between striatal FP-CIT uptake and echogenicity of the SN, neither contralateral to the clinically more affected body side (r = +0.08, P = 0.57; Pearson's correlation) nor ipsilateral (r = +0.01; P = 0.92). Our data show that the extent of SN hyperechogenicity does not correlate with the degeneration of presynaptic dopaminergic nerve terminals. Obviously SN hyperechogenicity and degeneration of presynaptic dopaminergic nerve terminals exist independently from each other and may be based on different pathomechanisms.

[1]  D. Berg,et al.  Differentiation of Parkinson’s disease and atypical parkinsonian syndromes by transcranial ultrasound , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[2]  J. Seibyl,et al.  Effect of treatment with L‐dopa/carbidopa or L‐selegiline on striatal dopamine transporter SPECT imaging with [123I]β‐CIT , 1999, Movement disorders : official journal of the Movement Disorder Society.

[3]  E. Wolters,et al.  Imaging of dopamine transporters with [123I]FP‐CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease , 2001, Synapse.

[4]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[5]  Uwe Walter,et al.  Brain parenchyma sonography discriminates Parkinson’s disease and atypical parkinsonian syndromes , 2003 .

[6]  Ingeborg Goethals,et al.  Analysis of clinical brain SPECT data based on anatomic standardization and reference to normal data: an ROC-based comparison of visual, semiquantitative, and voxel-based methods. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. , 2002, JAMA.

[8]  A. Seidler,et al.  Possible environmental, occupational, and other etiologic factors for Parkinson's disease , 1996, Neurology.

[9]  J. C. Stoof,et al.  [123I]β-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson’s disease , 2003, Journal of neurology, neurosurgery, and psychiatry.

[10]  Daniela Berg,et al.  Echogenicity of substantia nigra determined by transcranial ultrasound correlates with severity of parkinsonian symptoms induced by neuroleptic therapy , 2001, Biological Psychiatry.

[11]  B U Meyer,et al.  Brain parenchyma sonography discriminates Parkinson’s disease and atypical parkinsonian syndromes , 2002, Neurology.

[12]  Daniela Berg,et al.  Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. , 2002, Archives of neurology.

[13]  D. Berg,et al.  Perspectives of B-Mode Transcranial Ultrasound , 2002, NeuroImage.

[14]  Daniela Berg,et al.  Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings , 2001, Journal of Neurology.

[15]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[16]  G Becker,et al.  Vulnerability of the nigrostriatal system as detected by transcranial ultrasound , 1999, Neurology.

[17]  D J Wyper,et al.  Correlation of Parkinson's disease severity and duration with 123I‐FP‐CIT SPECT striatal uptake , 2000, Movement disorders : official journal of the Movement Disorder Society.

[18]  P N Karnauchow,et al.  Accuracy of clinical diagnosis. , 1982, Canadian Medical Association journal.

[19]  R. Rosenfeld,et al.  The Transition from Adolescence to Adult Life: Physiology of the ‘Transition’ Phase and Its Evolutionary Basis , 2003, Hormone Research in Paediatrics.

[20]  R. Benecke,et al.  Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson's disease , 2002, Journal of Neural Transmission.

[21]  D. Berg,et al.  In vivo detection of iron and neuromelanin by transcranial sonography: A new approach for early detection of substantia nigra damage , 2005, Movement disorders : official journal of the Movement Disorder Society.

[22]  W. Thurlbeck.  Accuracy of clinical diagnosis , 1982 .

[23]  P. Bauer,et al.  Screening for mutations of the IRP2 gene in Parkinson’s disease patients with hyperechogenicity of the substantia nigra , 2004, Journal of Neural Transmission.

[24]  C D Marsden,et al.  Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. , 1991, Brain : a journal of neurology.

[25]  S. Gacinovic,et al.  Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]‐FP‐CIT SPECT imaging: The [123I]‐FP‐CIT study group , 2000, Movement disorders : official journal of the Movement Disorder Society.

[26]  G Becker,et al.  Iron accumulation in the substantia nigra in rats visualized by ultrasound. , 1999, Ultrasound in medicine & biology.

[27]  Marc Laruelle,et al.  SPECT imaging of dopamine and serotonin transporters with [123I]β‐CIT: Pharmacological characterization of brain uptake in nonhuman primates , 1993, Synapse.

[28]  Daniela Berg,et al.  Five‐year follow‐up study of hyperechogenicity of the substantia nigra in Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.

[29]  Magnetic resonance relaxometry in Parkinson's disease , 2002, Neurological Sciences.

[30]  S. Houle,et al.  Influence of l-dopa and pramipexole on striatal dopamine transporter in early PD , 2001, Neurology.